Pharmacokinetics 101: How Drugs Work in Your Body

Written by Jay, Licensed Pharmacist

March 8, 2026 · Reviewed for clinical accuracy

You swallow a pill. Then what?

For most people, the pill disappears into a black box. You take it, something happens, and eventually it wears off. But there is an extraordinarily precise biological process unfolding behind the scenes — one that determines when the drug starts working, how strong the effect is, how long it lasts, and why two people taking the same dose of the same drug can have completely different experiences.

That process is pharmacokinetics — the study of what the body does to a drug. It is usefully contrasted with pharmacodynamics, which studies what the drug does to the body. You can think of it this way: pharmacokinetics governs the drug's journey, pharmacodynamics governs the drug's mechanism. Both together determine the clinical outcome you experience.

Pharmacokinetics is organized around four sequential processes, collectively abbreviated as ADME: Absorption, Distribution, Metabolism, and Elimination. Each stage has its own biology, its own variables, and its own clinical implications. Let us walk through them one by one.

A — Absorption: getting the drug into the bloodstream

Absorption is the process by which drug molecules move from the site of administration into systemic circulation. For an oral tablet, this means traversing the gastrointestinal (GI) tract and entering the blood. For an intravenous injection, there is no absorption phase — the drug enters the bloodstream directly, which is why IV drugs have immediate onset and their bioavailability is defined as exactly 100%.

The oral absorption pathway

When you swallow a tablet, it disintegrates in the stomach and the drug dissolves into solution. Drug molecules then cross the epithelial lining of the small intestine — primarily by passive diffusion down a concentration gradient, though some drugs use active transport mechanisms. From the intestinal wall, the drug enters the portal venous system and travels to the liver before reaching systemic circulation.

Several factors determine how quickly and completely this happens:

• GI pH: Weakly acidic drugs (like aspirin) are better absorbed in the acidic stomach environment, while weakly basic drugs (like many antibiotics) absorb better in the alkaline small intestine. Proton pump inhibitors raise gastric pH and can reduce the absorption of drugs that need an acid environment to dissolve.
• Food and gastric emptying: Food slows gastric emptying, which delays absorption and lowers the peak concentration (C_max). For some drugs, food reduces absorption significantly (tetracycline, bisphosphonates). For others, food actually increases absorption by promoting dissolution or reducing first-pass metabolism (e.g., griseofulvin, lopinavir).
• Drug formulation: Immediate-release formulations deliver the drug quickly. Extended-release or controlled-release formulations use polymer matrices or coatings to slow drug release, smoothing out the concentration-time curve and allowing less frequent dosing.
• Drug solubility and permeability: A drug must dissolve (solubility) and then cross biological membranes (permeability). The Biopharmaceutics Classification System (BCS) classifies drugs across these two axes, which directly predicts absorption behavior and helps design formulations.

Bioavailability (F) and why some drugs cannot be taken orally

Bioavailability (F) is the fraction of the administered dose that reaches systemic circulation unchanged. Oral bioavailability is almost always less than 100% because some drug is lost during absorption and some is metabolized by the liver before reaching the bloodstream (the first-pass effect, discussed under Metabolism).

Insulin is the canonical example of a drug that cannot be administered orally. As a peptide hormone, insulin is broken down by digestive proteases (stomach and intestinal enzymes) before it can be absorbed intact. Even if some survived digestion, the large molecular size would prevent absorption across the intestinal wall. This is why insulin must be injected subcutaneously or given intravenously. The same limitation applies to other protein-based drugs: monoclonal antibodies, GLP-1 agonists like semaglutide (though oral formulations using absorption enhancers are now FDA-approved), and many other biologics.

T_max: time to peak concentration

T_max is the time after administration at which plasma concentration reaches its highest point. For most oral tablets in fasted adults, T_max is 30 minutes to 2 hours. This matters clinically: if you take a painkiller 30 minutes before an expected headache becomes severe, the drug is likely near its peak when you need it most. Taking it too late means you are waiting for absorption while the pain escalates.

D — Distribution: the drug spreads through the body

Once a drug reaches the bloodstream, it does not stay there. The circulatory system acts as a highway, transporting the drug throughout every organ and tissue. Distribution describes how the drug partitions itself between blood and the various tissues and compartments of the body.

Volume of distribution (V_d)

Volume of distribution (V_d) is a theoretical parameter that describes how extensively a drug distributes outside the plasma. It is calculated as the total amount of drug in the body divided by the plasma concentration. A small V_d (close to plasma volume, roughly 3–5 L) suggests a drug stays mostly in blood — typical of large molecules like heparin and warfarin that are highly protein-bound. A large V_d (tens or hundreds of liters, far exceeding total body water at 42 L) indicates extensive tissue distribution — chloroquine, for example, has a V_d exceeding 200 L/kg, meaning it concentrates massively in tissues relative to plasma.

V_d has direct clinical consequences: drugs with very large volumes of distribution are extremely difficult to remove by dialysis, because only a tiny fraction is in the plasma at any time. If you try to dialyze a patient who has overdosed on amitriptyline (V_dapproximately 15 L/kg), dialysis removes only a minuscule portion of the drug burden.

Plasma protein binding

In the bloodstream, many drugs bind reversibly to plasma proteins — primarily albumin, but also alpha-1 acid glycoprotein and lipoproteins. Only the free (unbound) fraction of drug is pharmacologically active and available for distribution into tissues, metabolism by the liver, and elimination by the kidneys. A drug that is 99% protein-bound has only 1% free; if another drug displaces it, freeing it to 2%, the active drug concentration has doubled — a clinically significant interaction.

Hypoalbuminemia (low albumin levels, common in malnutrition, liver disease, and critical illness) can significantly increase the free fraction of highly protein-bound drugs like phenytoin, creating toxicity at doses that would be therapeutic in a healthy patient. This is one reason pharmacists routinely check albumin levels when interpreting drug concentrations.

The blood-brain barrier

The blood-brain barrier (BBB) is a selective physiological barrier formed by tight junctions between specialized endothelial cells in brain capillaries. It is designed to protect the central nervous system from pathogens and many toxic substances — and it does its job very well, which creates a problem for drug delivery. Only small, lipophilic (fat-soluble) molecules that are not substrates for efflux pumps can readily cross the BBB. This is why treating brain infections is so challenging: most antibiotics have poor CNS penetration. It is also why lipid-soluble drugs like diazepam act quickly on the brain while water-soluble ones like penicillin do not. Drug designers working on CNS conditions spend enormous effort engineering molecules that can cross this barrier.

M — Metabolism: the liver transforms the drug

Metabolism (also called biotransformation) is the process by which the body chemically modifies drug molecules, typically to make them more water-soluble and therefore easier to excrete via the kidneys. The liver is the primary site, though the gut wall, lungs, kidneys, and skin also perform metabolic transformations to varying degrees.

Phase I reactions: functionalization

Phase I reactions introduce or unmask a reactive chemical group on the drug molecule — typically through oxidation, reduction, or hydrolysis. The cytochrome P450 (CYP) enzyme superfamily carries out the majority of Phase I oxidations. The most clinically important CYP isoforms are CYP3A4 (responsible for metabolizing roughly 30–50% of all marketed drugs), CYP2D6, CYP2C9, CYP2C19, and CYP1A2.

Phase I metabolites are often less pharmacologically active than the parent drug, but this is not always the case. Some metabolites are more active (codeine is converted to morphine by CYP2D6 — its active metabolite provides the analgesia), and some are toxic (acetaminophen is partially converted to NAPQI, a reactive intermediate that causes liver damage in overdose).

Phase II reactions: conjugation

Phase II reactions conjugate (attach) a large polar molecule to the drug or its Phase I metabolite: glucuronic acid (glucuronidation), sulfate (sulfation), acetyl groups (acetylation), amino acids, or glutathione. These bulky additions dramatically increase water solubility and facilitate renal or biliary excretion. Phase II products are almost always pharmacologically inactive — the body has rendered the drug inert and ready for elimination.

The first-pass effect

The first-pass effect (or presystemic metabolism) is a critical concept for oral drugs. After absorption from the gut, drug molecules enter the portal vein and pass through the liver before reaching systemic circulation. The liver, being the metabolic powerhouse that it is, may extract and metabolize a significant fraction of the drug before it ever reaches its target tissue.

Nitroglycerin is a dramatic example: nearly 100% of an oral dose is destroyed by first-pass metabolism, rendering oral administration useless for acute chest pain. This is why nitroglycerin is given sublingually (under the tongue), where it absorbs directly into systemic circulation, bypassing the portal system entirely. The same drug, the same molecule, works or does not work depending solely on how it enters the body.

Propranolol has approximately 25% oral bioavailability due to first-pass metabolism; morphine has about 30%. Oral dosing must account for this loss, which is why oral doses are often substantially larger than equivalent intravenous doses.

Prodrugs

A prodrug is a pharmacologically inactive compound that is converted into the active drug after administration — the opposite of what we typically think of as metabolism. Prodrugs are designed intentionally, often to improve oral bioavailability, increase stability, or target drug release to specific tissues. Enalapril (an ACE inhibitor for hypertension) is inactive as swallowed; liver esterases convert it to enalaprilat, the active form. Codeine relies on CYP2D6 conversion to morphine for its analgesic effect — which means poor CYP2D6 metabolizers receive no pain relief from codeine, while ultrarapid metabolizers may receive dangerous morphine concentrations from standard doses.

Why grapefruit juice matters

E — Elimination: the final exit

Elimination is the irreversible removal of drug from the body. The kidneys handle the majority of drug elimination for water-soluble compounds and metabolites, but the biliary system (via the liver and intestines), the lungs, sweat, and breast milk also contribute in drug- and context-specific ways.

Renal excretion

The kidneys filter blood through the glomerulus and excrete water-soluble substances in urine. Renal drug elimination involves three processes: glomerular filtration (passive, based on molecular size and protein binding), active tubular secretion (a carrier-mediated process that can clear drugs faster than filtration alone), and passive tubular reabsorption (lipophilic molecules can diffuse back into the bloodstream from tubular fluid, reducing excretion).

Urinary pH affects reabsorption: a basic environment ionizes acidic drugs, preventing reabsorption and increasing excretion. This principle is exploited clinically in aspirin overdose treatment — alkalinizing the urine with sodium bicarbonate traps ionized salicylate in the tubular fluid and accelerates its excretion.

Biliary excretion and enterohepatic recirculation

Some drugs and metabolites are excreted by the liver into bile, which enters the small intestine. If intestinal bacteria then hydrolyze the conjugated metabolite back to active drug, it can be reabsorbed into the portal circulation — a loop called enterohepatic recirculation. This effectively extends a drug's half-life and duration of action. Interrupting this cycle (for example, with certain antibiotics that kill the relevant gut flora) can sometimes reduce drug efficacy. Estrogens in combined oral contraceptives undergo significant enterohepatic recirculation, which is part of why concurrent antibiotic use historically raised concern about contraceptive failure (though current evidence suggests the interaction is minimal for most antibiotics).

First-order vs. zero-order elimination kinetics

Most drugs follow first-order kinetics: a constant fraction of the drug is eliminated per unit time. As the concentration falls, the absolute rate of elimination falls proportionally. This is the basis of drug half-life — and it means the half-life remains constant regardless of concentration.

A small number of drugs follow zero-order kinetics: a constant amount is eliminated per unit time, regardless of concentration. This happens when the elimination pathway is saturated — the metabolic enzyme or transport protein is working at maximum capacity. Ethanol (alcohol) is the most familiar example: the liver's alcohol dehydrogenase is saturated at typical drinking concentrations, so the body eliminates roughly 7–10 g of alcohol per hour regardless of the blood alcohol level. There is no true half-life for ethanol in the pharmacokinetic sense. Aspirin at high doses and phenytoin at therapeutic doses also show zero-order (saturable) kinetics — making them significantly harder to dose safely, since small dose increases can produce disproportionately large concentration increases.

Half-life as the measure of elimination rate

For first-order drugs, half-life elegantly summarizes the entire elimination process into a single number. It incorporates both metabolic clearance (how fast the liver transforms the drug) and renal clearance (how fast the kidneys excrete it). The overall clearance (CL) of a drug is related to half-life and volume of distribution by:

A drug can have a long half-life because it distributes extensively into tissues (high V_d), even if its metabolic clearance is actually quite fast. Conversely, a drug with very high clearance and low volume of distribution will have a short half-life. This relationship is why organ impairment affects half-life differently depending on whether the drug is primarily cleared renally, hepatically, or both.

The concentration-time curve: reading the story of a dose

If you were to take blood samples every 30 minutes after swallowing a tablet and plot plasma drug concentration over time, you would get a characteristic curve: a rising phase as absorption exceeds elimination, a peak, and then a falling phase as elimination dominates. This is the concentration-time curve — the fundamental read-out of a drug's pharmacokinetic behavior.

The therapeutic window concept explains why dosing precision matters. For drugs with narrow windows, even small deviations in absorption, metabolism, or renal function can push concentrations out of the safe zone — either into ineffectiveness below or toxicity above. Regular therapeutic drug monitoring (TDM) with blood tests is used for these drugs in clinical practice.

Why pharmacokinetics matters for you personally

Understanding your medication schedule

Every instruction on a medication label — take with food, take on an empty stomach, do not crush, take at the same time each day, allow 12 hours between doses — has a pharmacokinetic reason. Once you understand ADME, these instructions stop being arbitrary rules and become logical consequences of the drug's chemistry and the body's biology. Missing doses at irregular times is not merely inconvenient; for drugs with narrow therapeutic windows or short half-lives, it can mean spending hours outside the therapeutic range with real clinical consequences.

Food-drug interactions

Food interactions are not trivial considerations — they are direct pharmacokinetic interventions. High-fat meals can increase absorption of some drugs by 50% or more. Dairy products chelate (bind) fluoroquinolone antibiotics and tetracyclines in the gut, preventing absorption. Vitamin K-rich foods reduce the anticoagulant effect of warfarin by promoting clotting factor synthesis. Tyramine in aged cheeses causes dangerous blood pressure crises in patients taking MAO inhibitors. These are not theoretical warnings — they represent well-documented pharmacokinetic and pharmacodynamic mechanisms.

Why you cannot simply double the dose

A common misconception is that if one tablet is good, two tablets are twice as good and work twice as fast. For most drugs this is incorrect and potentially dangerous. Doubling the dose raises C_maxproportionally, which may push concentrations above the MTC and into toxicity. It does not halve the time to effect — onset depends on T_max, which is primarily determined by absorption rate, not dose size. And it does not double the duration of effect in any linear way — because elimination is exponential, doubling the dose only extends duration by roughly one additional half-life. The correct response to inadequate drug effect is almost never to simply take more — it is to discuss dosing adjustment with a healthcare provider who can consider the full pharmacokinetic picture.

References & Further Reading

1. Brunton LL, Knollmann BC, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. McGraw-Hill; 2023.
2. Shargel L, Yu ABC. Applied Biopharmaceutics & Pharmacokinetics. 7th ed. McGraw-Hill; 2016.
3. Rowland M, Tozer TN. Clinical Pharmacokinetics and Pharmacodynamics. 4th ed. Lippincott Williams & Wilkins; 2011.
4. Toutain PL, Bousquet-Mélou A. Plasma terminal half-life. J Vet Pharmacol Ther. 2004;27(6):427-439.

Visualize the concentration-time curve yourself

The HalfLife simulator renders concentration-time curves in real time for 30+ common medications. See absorption peaks, exponential decline, accumulation with multiple doses, and steady state — all the concepts from this article, made visual and interactive.

CONTINUE LEARNING

Medical disclaimer

This article is intended for educational purposes only and does not constitute medical advice. The pharmacokinetic principles described are general in nature; actual drug behavior in any individual patient depends on numerous clinical variables including comorbidities, organ function, concurrent medications, and genetic factors. Do not use this information to self-diagnose, self-treat, or adjust medications without consulting a qualified healthcare professional. Always follow the guidance of your pharmacist or physician.